News

Vireo Growth Inc. to Release First Quarter 2025 Results on May 9, 2025

MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced…

8 months ago

Vireo Growth Inc. to Release First Quarter 2025 Results on May 9, 2025

MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced…

8 months ago

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 29, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through…

8 months ago

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 29, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through…

8 months ago

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in…

8 months ago

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in…

8 months ago

First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton

Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare…

8 months ago

First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton

Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare…

8 months ago

FYR Enters Know-How Agreement with Mayo Clinic to Collaborate on Blood-Based Biomarker Solutions for Parkinson’s Disease

Collaboration aims to use FYR’s AI-enabled EV-Omics (EVO) platform to produce dynamic, real-time insights into Parkinson’s diseaseMISSOULA, Mont., April 29,…

8 months ago

FYR Enters Know-How Agreement with Mayo Clinic to Collaborate on Blood-Based Biomarker Solutions for Parkinson’s Disease

Collaboration aims to use FYR’s AI-enabled EV-Omics (EVO) platform to produce dynamic, real-time insights into Parkinson’s diseaseMISSOULA, Mont., April 29,…

8 months ago